Approval Sought in Japan for New SARS-CoV-2 Vaccine
Source: Ed Arce  (7/7/23)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. More >

Co. Addresses Opioid Crisis Through Novel Platforms
Source: Boobalan Pachaiyappan  (7/7/23)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted. More >

New Psoriasis Drug Shown More Effective Than On-Market One
Source: Julian Harrison   (7/6/23)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report. More >

Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says
Source: Stefan Quenneville  (7/5/23)
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction. More >

Biotech Co. Remains Opportunity for Those With High Risk Tolerance
Source: Stefan Quenneville  (6/30/23)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note. More >

Q3: Chen Is Still Bullish on This Precious Metal
Source: Streetwise Reports  (6/29/23)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023. More >

New Drug for Bone Growth Disorder Improves Height Velocity
Source: Dr. Thomas Shrader  (6/21/23)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report. More >

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries
Source: Streetwise Reports  (6/16/23)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. More >

777% Gain Implied in Analyst's Target Price on Biopharma Co.
Source: Dr. Yi Chen  (6/14/23)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report. More >

Biotech Co. To Exit Health Care Services
Source: Streetwise Reports  (6/12/23)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future. More >

Key Catalyst for US Biopharma Stock on Track for Q4/23
Source: Ed Arce  (6/9/23)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report. More >

FDA Approval, Private Placement Funding Buoy Biotech Firm
Source: Streetwise Reports  (6/5/23)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement. More >

Analyst Says Pharma Co. 'Meaningfully Undervalued'
Source: Stefan Quennevill  (6/1/23)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note. More >

Animal Feed Company Evaluating Strategic Alternatives
Source: Streetwise Reports  (5/23/23)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit. More >

Biopharma Co. Ceases Program to Optimize Resources
Source: Hartaj Singh  (5/16/23)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. More >

Pharmaceutical Company Sets Gold Standard for New Drugs
Source: Streetwise Reports  (4/26/23)
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history. More >

As Countries Bolster Defense, Opportunities Emerge
Source: Streetwise Reports  (4/21/23)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability. More >

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial
Source: Streetwise Reports  (4/19/23)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. More >

Co.'s New Cell Therapy Shows Positive Effects
Source: Emily Bodnar  (4/19/23)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report. More >

Oncology Co. Receives Buy Rating for New Drug Trials
Source: Dr. Joseph Pantginis  (4/18/23)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report. More >

Biotech Rated Outperform Advances Top Drug Candidate
Source: Dr. David Nierengarten  (4/18/23)
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report. More >

Trial Results of New Pneumococcal Vaccine Compelling
Source: Dr. Thomas Shrader   (4/18/23)
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report. More >

Follow-up Results From T2 Diabetes Trial Positive
Source: Dr. Jonathan Aschoff   (4/14/23)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. More >

Biotech Co. Set To Reach New Highs
Source: Streetwise Reports  (4/13/23)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics. More >

Phase 3 Trial in Progress of New Ichthyosis Treatment
Source: Dr. Ram Selvaraju  (4/12/23)
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report. More >